Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MR-130A-01 patch ovulation suppression after intentional application errors
2025-522565-30-00Phase 2Authorised
- Sponsor
- Mylan
- Start
- Nov 2025
- Modality
- Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MR-130A-01 in contraception (3 arms), sponsored by Mylan. Primary endpoint: Ovulation incidence by application condition. Planned start Nov 2025; status: authorised.
02
Drugs
MR-130A-01
03
Conditions
contraception
Beyond the preview
Go deeper on 2025-522565-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522565-30-00.